To the best of our knowledge, only one phase III trial (Identifier: NCT04083339) has been conducted to test the safety and efficacy of AT-001 (aldose reductase inhibitor) in patients with DCM. The gene discussed is AKR1B1; the disease is familial dilated cardiomyopathy.